Focus: Oruka Therapeutics is a pre-revenue biotech focused on biologic therapeutics for dermatological diseases, headquartered in Waltham, MA. The company is in early clinical stages with a focused pipeline in plaque psoriasis.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Growing — net +12 jobs in 30d
15 jobs added vs 3 removed. Steady team buildout.
Best suited for early-stage biotech operators seeking meaningful clinical impact and equity upside with tolerance for pre-commercial uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Oruka Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Oruka Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
ORKA (NASDAQ: ORKA) supplement swaps Point72 for SILV Fund in 39.4M resale - Stock Titan
ORKA (NASDAQ: ORKA) supplement swaps Point72 for SILV Fund in 39.4M resale Stock Titan
Oruka Therapeutics (NASDAQ: ORKA) outlines 2026 director, auditor and pay votes - Stock Titan
Oruka Therapeutics (NASDAQ: ORKA) outlines 2026 director, auditor and pay votes Stock Titan
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Moderate Buy" from Brokerages MarketBeat
Oruka Therapeutics (ORKA) CMO sells 7,000 shares after exercising options - Stock Titan
Oruka Therapeutics (ORKA) CMO sells 7,000 shares after exercising options Stock Titan
ORKA (ORKA) files Rule 144 showing 21,000-share option exercise and 10b5-1 sales - Stock Titan
ORKA (ORKA) files Rule 144 showing 21,000-share option exercise and 10b5-1 sales Stock Titan
[EFFECT] Oruka Therapeutics, Inc. SEC Filing - Stock Titan
[EFFECT] Oruka Therapeutics, Inc. SEC Filing Stock Titan
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles